Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...
Objective To characterise the age-related impact of organ damage patterns on health-related quality of life (HRQoL) in ...
Lupus pathogenesis and autoimmunity are exacerbated by high fat diet-induced obesity in MRL/lpr mice
Objective SLE is an autoimmune disease characterised by persistent inflammation and autoantibody production. Genetic predisposition and environmental factors such as a high-fat diet (HFD) may ...
Background Systemic lupus erythematosus (SLE) is a complex autoimmune disease driven by pathological autoreactive T and B lymphocytes. Sphingosine 1-phosphate (S1P) regulates the egress of T and B ...
Background Povetacicept (ALPN-303) is an Fc fusion protein of a variant, engineered TACI domain, which mediates significantly more potent inhibitory activity than WT TACI-Fc or BAFF- or APRIL-specific ...
Objectives In SLE, deregulation of haematopoiesis is characterised by inflammatory priming and myeloid skewing of haematopoietic stem and progenitor cells (HSPCs). We sought to investigate the role of ...
Objective To systematically identify herbal supplements with immunostimulatory properties that may trigger or exacerbate autoimmune skin diseases. Methods We conducted a systematic scoping review in ...
Background In the phase 2 study JAHH (NCT02708095), treatment with baricitinib, an oral selective Janus kinase 1/2 inhibitor approved for the treatment of rheumatoid arthritis, resulted in significant ...
Background XmAb5871 is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcgammaRIIb. Co-ligation of CD19 and FcgammaRIIb inhibits B lineage cells key to lupus pathogenesis. This ...
LP-198 Clinical response by subgroups in patients with systemic lupus erythematosus (SLE) receiving standard of care treatment plus placebo (SOC+PBO): a post hoc analysis from clinical trial data (6 ...
Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback